Privia Health Q2 revenue misses estimates

Privia Health

07/08/2025 11:13

Overview

Privia Health Group Q2 revenue rises 23.4% yr/yr but missed analyst expectations

Adjusted EBITDA for Q2 beats analyst estimates, reflecting strong operational performance

Company raises FY 2025 guidance for practice collections and adjusted EBITDA

Outlook

Privia Health raises FY 2025 revenue guidance above high end

Company expects FY 2025 practice collections above high end

Privia Health sees FY 2025 adjusted EBITDA above high end

Company anticipates minimal capital expenditures for FY 2025

Result Drivers

IMPLEMENTED PROVIDERS - Increase of 13.8% in implemented providers compared to 2Q'24

PRACTICE COLLECTIONS - Practice collections rose 18.5% from 2Q'24

ADJUSTED EBITDA - Adjusted EBITDA increased by 31.6% compared to 2Q'24

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$521.20 mln
$800.10 mln (12 Analysts)
Q2 EPS
$0.02
Q2 Net Income
$2.70 mln
Q2 Adjusted EBITDA
Beat
$29 mln
$26.10 mln (18 Analysts)
Q2 Operating Income
$3.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Privia Health Group Inc is $30.00, about 34.1% above its August 6 closing price of $19.78

The stock recently traded at 72 times the next 12-month earnings vs. a P/E of 84 three months ago

Press Release: ID:nGNXbPVzZW

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)